Bazedoxifene: a selective estrogen-receptor modulator

Bazedoxifene is a third-generation selective estrogen-receptor modulator being developed for use alone or in combination with estrogen for prevention and treatment of osteoporosis in postmenopausal women. Preliminary clinical trials are encouraging. Bazedoxifene has been found to be efficacious in r...

Full description

Saved in:
Bibliographic Details
Published in:Women's health (London, England) England), 2008-07, Vol.4 (4), p.319-326
Main Author: Mitwally, Mohamed FM
Format: Article
Language:English
Subjects:
bazedoxifene
Bioavailability
Bone Density Conservation Agents - administration & dosage
Breast cancer
Clinical Trials, Phase III as Topic
Drug dosages
Drug therapy
Estrogens
FDA approval
Female
Fractures
Health aspects
Hot Flashes - prevention & control
Humans
Indoles - administration & dosage
menopause
Menopause - drug effects
Metabolism
Metabolites
Middle Aged
osteopenia
Osteoporosis
Osteoporosis, Postmenopausal - drug therapy
Postmenopausal women
Prevention
Selective Estrogen Receptor Modulators - administration & dosage
Selective Estrogen Receptor Modulators - adverse effects
selective estrogen-receptor modulators
Women's Health
Womens health
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Bazedoxifene is a third-generation selective estrogen-receptor modulator being developed for use alone or in combination with estrogen for prevention and treatment of osteoporosis in postmenopausal women. Preliminary clinical trials are encouraging. Bazedoxifene has been found to be efficacious in reducing bone turnover without adverse effects of breast pain. In Phase III studies, bazedoxifene was found to increase vasomotor symptoms when compared with placebo. This effect is similar to that of raloxifene. Lack of endometrial stimulation is another advantage. Current literature suggests that bazedoxifene is likely to be safe, well tolerated and effective for the treatment of postmenopausal osteoporosis. However, completion of Phase III clinical trials will further elucidate its safety and efficacy, as well as its advantages in comparison with other selective estrogen-receptor modulators.
ISSN:1745-5057
1745-5065
DOI:10.2217/17455057.4.4.319